Evolus
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
520 Newport Center Dr Ste 1200, Newport ...Phone Number
(949) 284-4555Website
www.evolus.comRevenue
$301.8 MillionStock Symbol
EOLSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Evolus
Evolus is a performance beauty company building an aesthetic portfolio of consumer brands in the cash-pay aesthetic market. Our flagship product is Jeuveau®, a proprietary neurotoxin formulation used in adults to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). Supported by a unique, customer-centric business model and innovative digital platform, Evolus is increasing its presence in the fast-growing aesthetic neurotoxin market. We also recently entered into an agreement to be the exclusive U.S. distributor of Evolysse, a line of five unique dermal fillers currently in late-stage development.Explore more
Evolus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evolus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Evolus is spiking on competitors!
Earning: See what the market has to say on Evolus recently announced quarterly report
Check if Evolus has recently received funding, and reach out quickly before it becomes old news!
Click to see if Evolus had a recent Job posting/layoffs
Evolus, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Evolus
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Evolus has new funding data
Product Launch: Get notified when Evolus launches new products
Recommended Actions
Reach out to Masked Content who joined Evolus as Masked Content
Find more new buyers
Compare Similar Companies to Evolus
Compare insights from companies similar to Evolus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Evolus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Evolus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Evolus.
Evolus financials insights
Gather financial insights about Evolus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$40M
Evolus Tech Stack
A closer look at the technologies used by Evolus
See more technologies
Most Recent Scoops
Person-Based
Product Launch, Business Development
Event
Person-Based
Events, Corporate Strategy, Podcast
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Product Launch, Business Development
Person-Based
Earnings, Financial Planning, Finance, Financial Operations
Evolus News & Media
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus (NASDAQ:EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO DavEvolus, Inc. Q4 2025 Earnings Call Summary
Moby summary of Evolus, Inc.'s Q4 2025 earnings callEvolus (EOLS) Q4 2025 Earnings Call Transcript
Nareg Sagherian: Thank you, Operator, and welcome to everyone joining us on today's call to review Evolus, Inc. fourth quarter and full year 2025 financial results. With me today are David Moatazedi, President and Chief Executive Officer, and Tatjana Mitchell, Chief Financial Officer.Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc. (NASDAQ:EOLS) to $15 from $19 while maintaining an Outperform rating, reflecting updated expectations following a softer-than-anticipated preannounced fourth quarter. Despite the near-term adjustment, the continued Outperform stance […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evolus
Sign Up For FreeTo access detailed company insights
Evolus is a performance beauty company building an aesthetic portfolio of consumer brands in the cash-pay aesthetic market. Our flagship product is Jeuveau®, a proprietary neurotoxin formulation used in adults to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). Supported by a unique, custo... Read More
